Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Dear Biotech Investors: Novavax’s Comparable Vaccine Matters

By Chris Lau, InvestorPlace Contributor

Researchers compared Novavax’s vaccine to three others on the market, offering a thorough glimpse of protection from boosters.

How Nio’s Stock Will React to Recently Posted EV Deliveries

By Chris Lau, InvestorPlace Contributor

Nio’s Q1/2022 deliveries and improving gross margins in the last quarter should remove all bearish fears that hurt the stock.

Snap Stock Will Go Back Up, Here’s Why

By Chris Lau, InvestorPlace Contributor

Snapchat’s growing social media presence is a positive catalyst that will send the stock back to previous highs.

Coinbase Stock Is Ready Reach $240 (and Beyond)

By Chris Lau, InvestorPlace Contributor

COIN stock consolidated at $160 in the last few months, setting an imminent rally as crypto investors chase Bitcoin’s rise.

7 No-Brainer Stocks to Buy for April

By Chris Lau, InvestorPlace Contributor

Start your stock scan with companies showing strong quant scores in value, growth and quality, then buy those with strong catalysts.

Load More